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Abstract
Most patients with epithelial ovarian cancer (EOC) experience drug-resistant disease recurrence. Identification of
new treatments is a high priority, and preclinical studies in mouse models of EOC may expedite this goal. We
previously developed methods for magnetic resonance imaging (MRI) for tumor detection and quantification in
a transgenic mouse model of EOC. The goal of this study was to determine whether three-dimensional (3D) fluo-
rescence molecular tomography (FMT) and fluorescent molecular imaging probes could be effectively used for
in vivo detection of ovarian tumors and response to therapy. Ovarian tumor–bearing TgMISIIR-TAg mice injected
with fluorescent probes were subjected to MRI and FMT. Tumor-specific probe retention was identified in vivo by
alignment of the 3D data sets, confirmed by ex vivo fluorescent imaging and correlated with histopathologic find-
ings. Mice were treated with standard chemotherapy, and changes in fluorescent probe binding were detected by
MRI and FMT.Ovarian tumorswere detected using probes specific for cathepsin proteases,matrixmetalloproteinases
(MMPs), and integrin αvβ3. Cathepsin and integrin αvβ3 probe activation and retention correlated strongly with tumor
volume. MMP probe activation was readily detected in tumors but correlated less strongly with tumor volume. Tumor
regression associated with response to therapy was detected and quantified by serial MRI and FMT. These results
demonstrate the feasibility and sensitivity of FMT for detection and quantification of tumor-associated biologic targets
in ovarian tumors and support the translational utility of molecular imaging to assess functional response to therapy
in mouse models of EOC.
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Introduction
Epithelial ovarian cancer (EOC) is the most common form of ovar-
ian cancer. Localized ovarian tumors are typically associated with
nonspecific symptoms, and the majority of women present with dis-
seminated peritoneal disease [1]. Although most patients respond
well to aggressive surgical debulking and combination chemotherapy
consisting of platinum and taxane, the majority experience disease
recurrence and ultimately drug resistance, making EOC the most
lethal of the gynecologic malignancies [1]. Hence, there is a critical
need to identify therapeutics that target pathways specific to ovarian
cancer tumor progression.
Targeting singlemolecules or pathways in tumor cells may initially show
efficacy; but these strategies may ultimately fail because of the develop-
ment of drug resistance based on mutation of the target, compensatory
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activation of alternate signaling pathways, or molecular heterogeneity
within the recurrent tumor. To better understand the mechanisms con-
tributing to drug resistance and the efficacy of combining targeted
agents, preclinical evaluation of investigational agents in mouse models
of EOC should be informative. We developed a transgenic mouse
model of spontaneous EOC by expressing the early region of SV40
under transcriptional control of the Müllerian-inhibiting substance
type II receptor [2]. Expression of SV40 TAg genes leads to functional
inactivation of p53, Rb, and Rb-related proteins and activation of
the AKT/mTOR pathway through inactivation of PP2A [3]. Results
from The Cancer Genome Atlas Research Network demonstrated
that these are the most common alterations that occur in high-grade
serous ovarian carcinoma in women [4]. Female TgMISIIR-TAg
transgenic mice develop bilateral ovarian carcinomas with 100%
penetrance, and tumors are histologically similar to serous adeno-
carcinomas in women [5–7]. To facilitate studies of ovarian cancer
disease progression and response to therapy, we developed magnetic
resonance imaging (MRI) methods for longitudinal in vivo anatomic
tumor imaging and quantification [5]. Using MRI, we showed that
ovarian cancers in TgMISIIR-TAg mice respond to standard combi-
nation chemotherapy consisting of cisplatin and paclitaxel [5] and to
the mTOR-targeted agent RAD001 (everolimus) [8]. Because tumor
growth rate and response to therapy can be quantified, noninvasive
longitudinal imaging modalities such as MRI offer considerable ad-
vantages over end point assessments for preclinical studies evaluating
therapeutic efficacy.
Over the past decade, significant advances have been made in the
development and application of in vivo molecular imaging in mice
[9]. Molecular imaging technology uses fluorescent imaging probes
in conjunction with either fluorescence reflectance imaging (FRI)
or three-dimensional (3D) fluorescence molecular tomography
(FMT) [9]. Target-specific and enzyme activatable fluorescent
probes enable detection of molecules or biologic activities of tumors
and/or the tumor microenvironment in real time. Importantly, fluo-
rescent probe activation and retention can be quantified using FMT.
Although sensitive and quantitative, FMT provides somewhat lim-
ited anatomic information and spatial resolution. To overcome this
limitation, FMT is often coupled with an imaging modality that
provides good spatial and anatomic resolution, such as computed
tomography or MRI [10–12]. To date, most tumor models evalu-
ated by FMT are those that are engrafted subcutaneously or that
occur spontaneously close to the body surface (e.g., mammary cancer
models) [13,14]. In vivo FMT imaging of tumors in deeply em-
bedded organs is significantly more challenging than superficial
tumors and has not been reported for mouse models of ovarian
cancer [10,11].
The goals of this study were to 1) develop and validate methods
for in vivo fluorescent molecular imaging of spontaneous ovarian
tumor development in a transgenic mouse model of EOC, 2) devel-
op multimodal imaging strategies using MRI and FMT for fusion
of anatomic and molecular images of ovarian tumors in mice, and
3) determine the correlation of fluorescent optical imaging probe
signals with ovarian tumor volume, progression, and response to
therapy. Here we describe a dual MRI-FMT imaging approach for
detection and quantification of tumor-associated cathepsin protease
and matrix metalloproteinase (MMP) activities and integrin αvβ3
expression in ovarian carcinomas in living mice with fluorescent
molecular imaging probes. This molecular imaging strategy can be
used to detect tumor progression and response to therapy in vivo.
Materials and Methods
Transgenic Mice
Procedures were approved by the Fox Chase Cancer Center Insti-
tutional Animal Care and Use Committee, and mice were maintained
under specific pathogen-free conditions. TgMISIIR-TAg mice have
been described [2,5] and were genotyped by polymerase chain reaction
amplification of the TAg transgene. Mice were maintained on a stan-
dard diet (2018SX Teklad Global; Harlan Laboratories, Somerville,
NJ) and transitioned to a purified, alfalfa-free rodent chow (Teklad
AIN-76A; Harlan Laboratories) for a minimum of 24 hours before
fluorescent imaging to minimize fluorescence in the gut.
Cells and Culture Conditions
Murine ovarian carcinoma (MOVCAR) 5009 cells isolated from the
ascites of ovarian tumor-bearing TgMISIIR-TAgmice [2,7] were main-
tained in Dulbecco modified Eagle medium containing 4% fetal bovine
serum, penicillin/streptomycin (100 U/ml and 100 μg/ml, respectively),
and 1× insulin/transferrin/selenium (supplied as a 100× stock by Life
Technologies, Grand Island, NY). Cathepsin protease activity was eval-
uated using commercially available assay kits for detection of cathepsins B,
D, and L (ab65300, ab65302, and ab65306; Abcam, Cambridge, MA).
Briefly, 1 × 106 MOVCAR 5009 cells were plated and grown at 37°C for
24 hours, lysed, and assayed according to the manufacturer’s instructions.
Optical Imaging Agents
For optical imaging of ovarian tumors and cells, commercially avail-
able imaging probes designed to detect oncologic processes were used.
Tumor-associated cathepsin and MMP activities were detected with
ProSense or MMPSense, respectively, and tumor-associated integrin
receptor expression was detected with the integrin αvβ3–targeted probe
IntegriSense [15]. AnnexinVivo 750, which detects exposed phospha-
tidyl serine, was used for anatomic localization based on its retention in the
kidneys. All probes were purchased from PerkinElmer, Inc (Waltham,
MA), and were administered intravenously into anesthetized mice by
retro-orbital injection at a dose of 2.0 nmol for in vivo experiments.
In Vitro Detection of Optical Imaging Probes
Parallel cultures of MOVCAR 5009 cells were grown in the presence
and absence of cathepsin protease inhibitors (cathepsin B inhibitor III
[CA-074] or cathepsin L inhibitor [CAA0225]; EMD Chemicals, Inc,
Gibbstown, NJ) and MMP inhibitors (ARP-100; Tocris Bioscience,
Bristol, United Kingdom). For detection of both ProSense 680 and
MMPSense 680, 3 × 104 cells were seeded on fibronectin-coated cover-
slips in 24-well plates for 4 hours and treated with 1 μg/ml saponin to
facilitate binding and detection of hydrophobic probes. The medium
was replaced with fresh medium containing vehicle (0.2% dimethyl
sulfoxide), cathepsin inhibitor (20 μM CA-074 or 20 μM CAA0225)
or MMP inhibitor (1 μM of ARP-100). After incubating for 1 hour
in the presence or absence of protease inhibitors, 1 nmol/ml of ProSense
680 or MMPSense 680 was added, and cells were incubated for an
additional 18 hours. For integrin αvβ3 detection, parallel cultures of
3 × 104 cells were grown overnight and treated with 1 μg/ml saponin
for 15 minutes. Cells were then incubated in the presence of 0.2%
dimethyl sulfoxide or 100 nM echistatin, an integrin αvβ3 antagonist
(Tocris Bioscience) for 15 minutes, and then the medium was re-
placed with fresh medium containing 1 nmol/ml IntegriSense 680 and
cells were incubated for an additional 15 minutes. Coverslips were
washed with phosphate-buffered saline, fixed in 3% paraformaldehyde,
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counterstained with DAPI, and probe activation or binding was detected
by fluorescence microscopy.
Fluorescence Molecular Tomography
Before imaging, mice were anesthetized with isoflurane (Isosol;
Vedco, Inc, St Joseph, MO) at a concentration of 2% in medical-grade
O2, and fur around the lower thorax, the abdomen, and the back was
removed by shaving and depilation with a cosmetic hair removal lotion.
FMT was performed with the VisEn FMT2500 Quantitative Tomog-
raphy Imaging In Vivo Imaging System (PerkinElmer, Inc). Mice were
placed in a biplanar imaging cassette supplied with the instrument and
transilluminated with laser light. Resulting transmission and fluores-
cence patterns were captured with a thermoelectrically cooled CCD
camera, and the position and intensity of fluorescence sources were re-
constructed in three dimensions using the TrueQuant software package
(Perkin Elmer), supplied with the FMT2500 [16]. For ProSense 680,
IntegriSense 680, or MMPSense 680, mice were injected with probes
and imaged 24 hours later. MMPSense 750 was injected 14 hours be-
fore imaging, and AnnexinVivo 750 was injected 2 hours before imag-
ing. All mice were imaged in the both the 680- and 750-nm channels
and imaging times totaled approximately 15 minutes for each mouse.
Magnetic Resonance Imaging
MRI was performed in a vertical-bore 7-T magnet with a Bruker
DRX300 spectrometer (Bruker Biospin Corporation, Billerica, MA)
and ParaVision 3.0 software (Bruker Biospin Corporation) as described
[5,17]. A custom-built transfer cassette constructed of a Lucite frame
and 0.12-mm-thick mylar windows was used. Both the FMT andMRI
cassettes compressed the mice to an equal thickness of 15.0 mm. To
ensure accurate image fusion, mice were positioned in precisely the same
orientation when transferred from one cassette to another, aligning the
inferior-superior axis parallel to the edges of the cassette. Contrast-
enhanced MRI was performed as described [5]. Alternatively, mice
were imaged using a T2-weighted fast spin echo (rapid acquisition
with refocused echoes), which could be completed quickly (∼2 min
35 sec) and did not require gadolinium contrast enhancement (T R =
2400 milliseconds, T E = 8.8 milliseconds, rapid acquisition with re-
focused echoes factor = 8, effective echo time = 37 milliseconds, slice
thickness = 0.75 mm, field of view = 2.56 cm, in-plane resolution =
0.1 mm, and signal average = 2). Image data sets were converted to Ana-
lyze image format and tumor volumes calculated using MRIcro [18]
(http://www.cabiatl.com/mricro/) as described [5].
A full-body-thickness MR data set for rendering with FMT was gen-
erated using a 3D gradient echo with T R = 200 milliseconds, T E =
2.3 milliseconds, flip angle = 60 degrees, and number of excitations =
1 imaging sequence. The acquisition matrix of 256 × 192 × 96 was
zero-filled and reconstructed to a matrix of 256 × 256 × 128. The field
of view was 3 × 3 × 1.5 cm for an isotropic voxel size of 0.13 mm.
Image Fusion
FMT and MRI data sets were fused using freely available A Medi-
cal Imaging Data Examiner (AMIDE) software [19] (http://amide.
sourceforge.net/). TrueQuant software permitted exportation of the
FMT data sets in DICOM format, whereas the MRI data sets were
imported directly into AMIDE, with the relevant scan geometry
information entered manually. Image fusion of the two data sets was
done using the kidneys as internal fiducial markers. The kidneys were
marked and detected in the FMT data set by kidney-specific binding
of AnnexinVivo 750 probe, and the data sets were aligned and rotated
until the kidneys overlapped in three dimensions. The same transfor-
mations that aligned the kidneys in the two data sets were then applied
to the FMT data set from the 680-nm channel. The position of the
ovaries (or ovarian tumors) relative to the kidneys in the MR data set
was noted, and the areas corresponding to ovary were then identified
on the FMT data sets as displayed in the TrueQuant software and
regions of interest (ROIs) were drawn. The ROIs drawn were of
similar volume to those calculated directly from the MR data set.
The absolute value of probe retention in the ROI was measured in
picomoles (calculated by TrueQuant).
Ex Vivo FRI
After in vivo imaging, mice were euthanized, dissected to expose
the abdominal cavity, and imaged in an IVIS Spectrum (Caliper Life
Science, Hopkinton, MA) fluorescent/bioluminescent imaging system.
Fluorescent images were acquired with 0.5-second exposure times at
f -stop = 2. The 680-nm probes were imaged with an excitation wave-
length of 640 nm and emission of 700 nm, and the 750-nm probes
were imaged with an excitation wavelength of 710 nm and emission at
760 nm. After imaging of the abdomen, mice were further dissected,
and excised organs, including the ovaries, the reproductive tract, the
kidneys, the intestine, the liver, the spleen, and the lungs, were imaged
with the same parameters. ROIs were drawn around each ovarian tumor,
and the total radiant efficiency ([p/s]/[μW/cm2]), as calculated by the
Living Image software (supplied with IVIS Spectrum), was recorded.
Chemotherapy
To detect response to chemotherapy with fluorescent probes and
FMT, mice were first imaged with MRI to confirm the presence
and volume of ovarian tumors. Normal ovaries are approximately
10 mm3; therefore, the minimum size threshold for initiation of
chemotherapy was defined as 25 mm3. Mice were treated with a stan-
dard combination chemotherapy consisting of cisplatin (6 mg/kg,
injected intraperitoneally four times at 4-day intervals) and paclitaxel
(10 mg/kg, injected intraperitoneally six times at 2-day intervals) or
vehicle (phosphate-buffered saline).
Tissue Preparation and Immunohistochemistry
Mice were euthanized by CO2 asphyxiation and examined by
necropsy. Tumor length (l ) and width (w) was measured with calipers
and volume calculated (l × w2 × 0.5). Entire reproductive tracts were
removed, fixed in 10% (vol/vol) neutral buffered formalin overnight,
and submitted for processing. Ovarian tumors were confirmed by eval-
uation of tissue sections stained with hematoxylin and eosin (H&E)
and antibodies recognizing the SV40 TAg (pAB101, 1:100; Santa Cruz
Biotechnology, Santa Cruz, CA) as described [2].
Statistical Analysis
Linear regression analyses were used for comparisons of tumor vol-
ume and probe retention. Correlations (R2 values) for each compari-
son were calculated, and statistical analyses were performed using a
two-tailed unpaired Student’s t test. P ≤ .05 was considered signifi-
cant. Comparisons of tumors in chemotherapy-treated and vehicle-
treated mice were based on four summary observations per group
and done using the one-sided Wilcoxon two-sample test.
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Results
Fluorescent Probe Activation and/or Binding in
MOVCAR Cells
To develop methods for detecting ovarian tumors by FMT, fluores-
cent molecular probes recognizing tumor-associated molecules or
biologic activities were required. Among the available imaging agents
were probes selectively activated by cathepsin proteases and MMPs
and probes that bind to the tumor-associated integrin αvβ3. Human
ovarian carcinomas commonly exhibit increased activity and/or expres-
sion of cathepsin [20–22], MMPs [23,24], and integrin αvβ3 [25–27];
thus, these three classes of probes were logical candidates for FMT de-
tection ovarian tumors. Before the in vivo experiments, we evaluated
in vitro activation and/or binding of each probe in MOVCAR 5009
cells [2,7]. The extent and subtype of cathepsin expression in ovarian
tumors and tumor-derived cell lines were unknown; therefore, the
expression of cathepsins B, D, and L was evaluated using commer-
cially available assays. Low-level cathepsin B activity was detected in
MOVCAR cells but was not inhibited by the cathepsin B–specific
inhibitor CA-074, suggesting that it was nonspecific (Figure 1A). Little
or no cathepsin D activity was detected and was not lysate concentra-
tion dependent (Figure 1A). Concentration-dependent cathepsin L
activity was detected, and this activity was significantly inhibited by
the cathepsin L-specific inhibitor CAA0225 (Figure 1A), suggesting
that it is the predominant cathepsin activated in tumor cells. ProSense
is an optically silent imaging probe that becomes strongly fluorescent
on cleavage by cancer-associated cathepsins, including cathepsin
L. MOVCAR cells incubated in the presence of ProSense exhibited
a strong fluorescent signal that was significantly inhibited by the addi-
tion of CAA0225 but unaffected by CA-074 (Figure 1B). These re-
sults are consistent with the enzyme assays and show that ovarian
tumor cells express cathepsin protease activity necessary for ProSense
probe cleavage and activation.
Cell lines and primary ovarian tumors from TgMISIIR-TAg mice
express MMP-2 and MMP-9 (F. Xiao and D. Connolly, unpublished
data). Consistent with this, MOVCAR cells incubated in the presence
of MMPSense (an MMP-activatable probe) exhibited a strong fluo-
rescent signal that was significantly decreased in the presence of the
MMP inhibitor ARP-100 (Figure 1C ). The integrin αvβ3–targeted
probe, IntegriSense, also bound to MOVCAR cells, and preincuba-
tion with the integrin αvβ3 antagonist echistatin significantly inhibited
this binding (Figure 1D). Taken together, these data show that like
human EOCs, tumor cells derived from TgMISIIR-TAg mice ex-
press tumor-associated cathepsins, MMPs, and integrin αvβ3 and that
fluorescent probes targeting these proteins would be useful for in vivo
optical imaging.
Dual MRI and FMT Imaging and Image Alignment
FMT has been used successfully to image subcutaneous and super-
ficial tumors in mice [28,29], but imaging tumors in deeply em-
bedded abdominal organs is significantly more challenging owing
to limited tissue penetration and light scattering. An additional tech-
nical challenge is the presence of dark fur and pigmentation in mouse
strains commonly used to develop genetically engineered mouse
models of cancer. Data regarding the feasibility of optical imaging
of abdominal organs using FMT in black mice are limited; therefore,
we first evaluated ProSense probe activity in wild-type C57BL/6 mice.
Resulting images showed background probe signal in the abdominal
cavity including the gastrointestinal tract and liver (Figure W1A).
To provide additional anatomic data for definitive identification of
probe signal emanating specifically from ovaries and ovarian tumors,
we sought to combine anatomic imaging byMRI with optical imaging
by FMT.
Mice are placed horizontally in the FMT2500 imaging system and
vertically (head up) in the MRI system; therefore, potential positional
shifts of organs due to gravity needed to be addressed for subsequent
alignment of MR and FMT images. Software on the imaging systems
did not provide for definition of the skin surface to aid in alignment.
However, the data as reconstructed are intrinsically volumetric and
could be registered directly with a minimum of processing. The planar
surfaces of the imaging cassettes were the most clearly defined surfaces
and served as boundaries in both data sets as the first step in image
fusion. To further ensure correct alignment, we capitalized on the ob-
servation that AnnexinVivo 750 is specifically retained in the kidneys
of injected mice, resulting in nonoverlapping signals adjacent to nor-
mal ovaries or ovarian tumors (Figure W1, A and B). Based on the
adjacent posterior anatomic location of the ovaries with respect to
the kidneys, fluorescently marked kidneys could be effectively used
as an internal fiducial for alignment of the MR and FMT images.
Fluorescent images exported from the TrueQuant software in
DICOM (Figure W1A, subpanels a-c) were imported into AMIDE
(Figure W1A, subpanels d-f ) and aligned with MR images from the
same mouse using the fluorescent signal from the kidneys (FigureW2,
A-C ). In the aligned images from wild-type mice, ProSense probe
activation was undetectable in either ovary (Figure W2). The normal
histology and structure of the ovaries was confirmed by analyzing
H&E- and TAg-stained tissue sections (not shown).
In Vivo Detection of Cathepsin Activity in Ovarian Tumors
With established methods for MR and FMT image alignment,
in vivo detection of cathepsin activity in ovarian tumors was first
tested in mice with tumors of similar total volume as determined
by MRI (Figure W2). Mice were given intravenous injections of
ProSense 680 or ProSense 680 control (a nonactivatable analog) and
AnnexinVivo 750 and imaged sequentially by MRI and FMT. Data
sets were aligned and showed dorsal fluorescent signals that coaligned
with the ovarian tumors in the ProSense 680–injected mouse
(Figure W2). The specificity of probe activation was confirmed in
the ProSense 680 Control probe–injected mice, where there was no
detectable signal at the position of the ovarian tumors (Figure W2).
Having confirmed that we could detect cathepsin protease activity in
ovarian tumors, we then evaluated a larger cohort of mice including
three wild-type C57BL/6 mice and 15 TgMISIIR-TAg mice ranging
in age from 107 to 192 days (mean age = 143 days). Aligned data sets
(Figure 2, A-C ) were used to determine the position of the ovaries and
assign ROIs for signal quantification (Figure 2D). Negligible probe
activation was observed in wild-type C57BL/6 mice (Figure W2 and
data not shown) but was consistently observed in the ovaries of
TgMISIIR-TAgmice. In mice with normal-sized or minimally enlarged
ovaries (e.g., mouse 9374; Figure 2A), discrete fluorescent signals were
detected at the position of the ovary (Figure 2, B-D). Ex vivo fluorescent
images of the exposed abdominal cavity and dissected organs (Figure 2,
E-H) confirmed the presence of fluorescent signals from AnnexinVivo
in the kidneys (Figure 2,E and F ) and ProSense in the ovaries (Figure 2,
G and H ). Although the ovaries from this mouse exhibited little or
no enlargement, H&E and TAg staining of tissue sections clearly
showed the presence of bilateral microscopic (∼200-600 μm in diameter)
ovarian tumors (Figure 2, I -L). In mice with large tumors, prominent
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ProSense signals were detected (Figure 3) and ex vivo images confirmed
the ROIs assigned in the FMT image correctly identified fluorescent
signals from the kidneys and the massively enlarged (∼900 mm3) left
ovarian tumor (Figure 3,E and F ). H&E andTAg stained sections also
confirmed the presence of a large tumor in the left ovary (Figure 3, I
and J ) and TAg-positive tumor cells in the right ovary (Figure 3,K and
L). Reconstruction and image rendering of 3D fused MR and FMT
images showed bilateral ovarian tumors in a TgMISIIR-TAg mouse
(Movie W1). This movie illustrates the dorsal position and extent of
the ovarian tumor-specific fluorescent signal in the context of the
whole animal and the close posterior location of the ovarian tumors
relative to the kidneys. Collectively, these data demonstrate that ovar-
ian tumors express cathepsin activity leading to probe activation and
retention. Importantly, tumor-associated cathepsin activity can be
Figure 1. Targetedmolecular fluorescent probes detect tumor-associated cathepsin, MMP and integrin αvβ3 in MOVCAR cells isolated from
tumor-bearing transgenic mice. (A) Lysates ofMOVCAR cells assayed for cathepsin activity showed little or no cathepsin B and D activity but
exhibited cathepsin L activity that was significantly inhibited by the addition of CAA0225. Mean values and SEM are shown for three inde-
pendent assays. Cathepsin L activity in untreated and CAA0225-treated cells was compared with unpaired t test. *P < .0001. (B) MOVCAR
cells incubated in the presence of ProSense 680 exhibit probe activation that is inhibited by the cathepsin L–specific inhibitor, CAA0225, but
not by the cathepsin B inhibitor CA-074. (C) MOVCAR cells incubated in the presence of MMPSense 680 exhibit probe activation that was
significantly inhibited by the addition of the MMP inhibitor ARP-100. (D) Integrin αvβ3 probe binding was detected by incubating MOVCAR
cells in the absence and presence of the integrin αvβ3 antagonist echistatin. Probe activation and retention were quantified by calculating
the mean fluorescent signal intensity in 10 cells per field in three image fields using ImageJ and analyzed by analysis of variance, followed
by the Tukey multiple comparison test (B, *P < .001) or by the unpaired t test (C and D, *P ≤ .001).
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detected at an early stage in microscopic ovarian tumors before ovarian
enlargement detectable by MRI.
Cathepsin-Mediated Probe Activation Correlates with
Tumor Size
Although the spatial resolution of FMT compares poorly with that
achievable by MRI for tumor volume quantification, the increased
fluorescent signal in mice with large tumors did suggest the possi-
bility that cathepsin activity correlated with tumor size. As this was
a first effort at in vivo fluorescent molecular imaging of ovarian tumors,
direct determination of the probe distribution and the relationship to
tumor volume is important to validate the use of fluorescent probes in
this model. To evaluate this further, the following comparisons were
made for ovarian tumors: 1) volume determined by MRI and caliper
measurements, 2) fluorescent probe retention and MRI volume, 3)
fluorescent probe retention and caliper volume, 4) ex vivo fluorescence
reflectance and MRI volume, 5) ex vivo fluorescence reflectance and
caliper volume, and 6) fluorescent probe retention and ex vivo fluores-
cence reflectance (Figure 4 and Table 1; data not shown). As shown
previously [5], an extremely strong correlation existed between tumor
volumes determined by MRI and caliper measurement (Figure 4A;
R2 = 0.99, P < .0000001). Similarly, cathepsin-mediated probe acti-
vation and retention in the ovary were highly correlated with tumor
volume determined by MRI (Figure 4B; R2 = 0.95, P < .00001) or by
caliper measurement (Figure 4C ; R2 = 0.96, P < .0000001). Signal
detected by ex vivo fluorescence reflectance also correlated with tumor
volume (R2 = 0.69 for MRI and R2 = 0.73 for calipers, P < .0000001)
and probe retention (R2 = 0.80, P < .0000001; data not shown).
Taken together, these results demonstrate that ProSense can be used
to detect ovarian tumors in TgMISIIR-TAg mice and that the level
of cathepsin activity present in the tumors is strongly correlated with
tumor size.
In Vivo Detection of αvβ3 Integrin Binding and
MMP Activity in Ovarian Tumors
Expression of integrin αvβ3 has been shown in human ovarian carci-
noma cell lines and is associated with motility and invasion mediated
by MMPs [25–27]. Based on the in vitro data confirming the detection
of integrin αvβ3 binding and MMP activity in MOVCAR cells (Fig-
ure 1), we evaluated IntegriSense and MMPSense for detection of
Figure 2. Detection of cathepsin activity in TgMISIIR-TAg mouse with small ovarian tumors. (A) MR image showing essentially normal-
sized ovaries (arrows) posterior to the kidneys (k). All MR and fluorescent images in this and in subsequent figures are shown from the
dorsal perspective, where the left side of the mouse is on the left side of the image. (B) Fused FMT-MR image showing AnnexinVivo 750
detection of kidneys (yellow-orange and ProSense 680 detection of ovarian tumors (green/blue). (C) Overlay of FMT signals on the MR
image. (D) TrueQuant image of the same mouse showing ROIs corresponding to kidney (red) and ovarian tumors (green/blue). Mice
were imaged ex vivo (E-H) using the IVIS imaging system. Images in E and F were taken with 710-nm excitation and 760-nm emission
filters, and those in G and H were taken with 640-nm excitation and 700-nm emission filters. After euthanasia, mice were partially dis-
sected to expose the intact reproductive tract and kidneys (E and G). The reproductive tracts, left ovary (lo), right ovary (ro), and other
organs, including liver (li), lung (lu), intestines (i), spleen (s), and kidney (k), were removed and imaged ex vivo using the 710/760 and 640/
700 filter pairs (F and H, respectively). H&E- (I and K) and TAg- (J and L) stained sections show the presence of microscopic ovarian
tumors (arrows) that exhibit strong nuclear TAg staining. Scale bars in H&E- and TAg-stained sections correspond to 500 μm.
456 Molecular Imaging of EOC in Transgenic Mice Hensley et al. Neoplasia Vol. 14, No. 6, 2012
ovarian tumors in vivo. TgMISIIR-TAg (n = 5) and wild-type (n = 2)
mice were injected with IntegriSense 680 and AnnexinVivo 750 and
imaged by MRI and FMT as described. Strong fluorescent signals were
detected in the ovarian tumors of all five of the TgMISIIR-TAg mice
(Figure 5, A-C) but not in the ovaries of wild-type C57BL/6 mice (not
shown). The presence of ovarian tumors was confirmed by histopath-
ologic evaluation of H&E- and TAg-stained sections (not shown).
Comparisons of probe retention and tumor volume showed that the
IntegriSense signal was strongly correlated with volume determined
by MRI (R2 = 0.93, P < .00001) or caliper measurement (R2 = 0.88,
P < .0001). These results demonstrate that integrin αvβ3 expression
can be detected in ovarian tumors in vivo using IntegriSense and that
probe binding correlates with tumor size.
MMP activity in ovarian tumors was evaluated with MMPSense
and was detected in ovarian tumors (Figure 5, D-F ) but not in normal
ovaries in wild-type mice (not shown). The presence of ovarian tumors
was confirmed by both ex vivo imaging and evaluation of H&E- and
TAg-stained sections for each case (not shown). The total amount of
MMP-mediated probe activation in ovarian tumors was generally
lower than the amount of cathepsin or integrin αvβ3 probe signal in
similar-sized tumors and comparisons of probe retention with tumor
volume showed that the absolute amount of MMPSense detected in
tumors correlated less well with tumor volume (R2 = 0.546 for MRI
and 0.5997 for calipers, P < .01; data not shown).
Detection of Tumor Progression and Response to
Chemotherapy by FMT
Primary ovarian tumors in TgMISIIR-TAg mice have a mean dou-
bling time of 7.3 days and are responsive to standard combination che-
motherapy consisting of cisplatin and paclitaxel [5]. Using detection
integrin αvβ3 probe binding as a surrogate for tumor size, we next test-
ed whether FMT could reliably detect tumor progression and response
to chemotherapy in TgMISIIR-TAgmice. Tumor-bearing mice (n = 8)
underwent MRI and FMT to determine baseline tumor volume and
IntegriSense retention. Mice (n = 4 per group) were then treated with
cisplatin and paclitaxel or vehicle and serially imaged by MRI and
FMT at 12-day intervals. Ovarian tumors in untreated mice pro-
gressed rapidly, exhibiting a tumor doubling time of approximately
1 week (Figure 6, A and C). The increase in tumor growth was also
reflected in a parallel increase in IntegriSense probe binding (Fig-
ure 6D). Mice treated with cisplatin and paclitaxel exhibited a reduction
in ovarian tumor volume detected by MRI (Figure 6, B and C ) and
Figure 3. Detection of cathepsin activity in TgMISIIR-TAgmousewith a large ovarian tumor. (A)MR image showing a large ovarian tumor on
the left (arrow) and the right kidney (k). (B) AMIDE image showing AnnexinVivo 750 detection of kidneys (yellow-orange) and ProSense 680
detection of the ovarian tumor on the left (red/yellow/green/blue). (C) Overlay of FMT signals on theMR image. (D) TrueQuant image of the
samemouse showingROIs corresponding to kidneys (red) and ovarian tumor on the left (red/yellow/green/blue).Micewere imaged ex vivo
(E-H) using the IVIS imaging system. Images were taken with either a 710/760-nm filter set (E and F) or a 640/700-nm filter set (G and H).
After euthanasia, mice were partially dissected to expose the intact reproductive tract and kidneys (E and G). The reproductive tracts, left
ovary (lo), right ovary (ro), and other organs, including liver (li), lung (lu), intestines (i), spleen (s), and kidney (k), were removed and imaged
ex vivo (F and H) using the 710 and 640 channels, respectively. H&E- (I and K) and TAg- (J and L) stained sections show the presence of a
large ovarian tumor on the left and TAg-positive tumor cells within the otherwise normal-sized right ovary (arrows) and outside the ovary
within the intrabursal space (arrowheads). Scale bars in H&E- and TAg-stained sections correspond to 500 μm.
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significantly decreased probe retention in the tumors (Figure 6, B and
D). Probe retention in the ovarian tumors mice remained strongly cor-
relatedwith tumor volume determined byMRI or calipermeasurements
(R2 = 0.92 and R2 = 0.86, respectively, P < .001; data not shown). To-
gether, these data show that ovarian tumor progression and response to
combination chemotherapy can be accurately assessed using FMT with
an integrin αvβ3–binding fluorescent probe.
Discussion
Using a dual MRI-FMT imaging approach, we confirmed the feasibil-
ity and sensitivity of detection of tumor-associated biologic activities in
ovarian carcinomas in living mice by FMT imaging with fluorescent
molecular imaging probes. For this study, we chose probes based on
their relevance to EOC. Among these, the ProSense, MMPSense, and
IntegriSense probes were considered to be highly relevant based on
prior studies showing high levels of expression and activity of cathep-
sins, MMPs, and integrin αvβ3 in human EOCs [20–27,30–35]. Al-
though immunohistochemical staining is commonly used for detection
of proteases in tumor tissues, the mere presence of these proteins does
not provide information about protease activity. An advantage of acti-
vatable fluorescent probes is that the probes are fluorescently quenched
until they are cleaved by active proteases. Thus, probe activation and
retention in tumors are directly reflective of tumor-associated protease
activity. The fluorescent molecular probes used detected cathepsin and
MMP activity and integrin αvβ3 binding in ovarian tumors but not in
Figure 4. Relationship between cathepsin-mediated ProSense 680 activation and tumor volume. Linear regression analysis of ovarian
tumor volume determined by MRI or caliper measurements and cathepsin-mediated activation of the NIRF imaging probe ProSense
680 in tumors. Data from in vivo imaging by MRI and FMT were analyzed to compare (A) tumor volume determined by MRI versus caliper
measurements, (B) probe retention versus MRI tumor volume, and (C) probe retention versus caliper tumor volume.
Table 1. Data Summarizing Probe Concentration (ProSense 680) and Ovarian Tumor Volume from TgMISIIR-TAg Mice.
Mouse No. Age (d) Tumor Volume (mm3)
Probe Concentration (pmol)Caliper MRI
Left Ovary Right Ovary Left Ovary Right Ovary Left Ovary Right Ovary
ProSense 680
9374 107 4.0 9.4 5.0 15.3 6.1 4.9
9375 107 4.5 12.6 5.8 9.1 12.3 12.9
9435 118 30.3 178.9 16.8 238.9 9.1 69.4
9336 122 968.8 7.8 866.8 5.6 292.0 5.2
9264 131 14.0 12.5 11.3 10.2 12.8 6.2
9660 132 732.1 5.3 757.3 6.5 174.7 8.6
9181 147 178.5 42.0 182.7 66.8 41.5 25.5
9180 147 24.5 15.3 14.9 8.38 11.0 29.4
9233 147 9.2 12.8 27.8 14.0 15.5 12.4
9319 154 152.1 409.1 181.7 386.2 12.2 24.7
9075 157 8.4 3.2 6.5 6.9 6.5 6.9
9077 157 174.0 22.3 138.0 11.9 67.4 5.9
9230 159 2174.2 122.4 1758.4 142.4 512.3 29.2
9320 174 77.5 191.1 85.7 168.9 13.4 26.3
9265 192 308.4 161.8 402.2 161.0 40.23 17.3
IntegriSense 680
9603 97 69.8 2258.3 44.8 1358.8 5.5 199.8
9315 125 3.3 10.3 11.8 23.5 0.0 24.9
9245 140 310.0 13.3 206.8 19.6 20.5 24.3
9232 147 487.4 134.6 430.0 141.3 112.3 46.0
9079 157 16 16.8 29.4 13.1 21.6 16.6
MMPSense 680
9661 139 473.8 1.8 379.7 5.8 19.1 1.0
9516 145 19.5 57.4 17.8 34.7 2.3 10.1
9646 148 793.2 654.2 585.6 803.0 67.1 41.7
9462 155 855.6 87.5 743.9 29.2 20.0 2.2
9698 157 4.0 537.0 14.5 460.2 2.9 12.5
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normal wild-type ovaries. Quantitative assessments showed that cathep-
sin activity and integrin αvβ3 binding were strongly correlated with
tumor volume. MMP activity was readily detected in ovarian tumors;
however, the correlation with tumor volume was not as strong. This
may be related to differences in: 1) overall MMP activity in tumors, 2)
lack of uniform MMP activity in tumors, or 3) intrinsic differences in
the imaging probes properties (e.g., inherent fluorescent signal strength
and/or capacity for tumor localization and penetration).
Advances in optical molecular imaging technologies offer the pos-
sibility of improved or alternative strategies for disease detection and
staging and for the identification and observation of molecules and/or
biologic activities associated with tumor initiation, progression and re-
sponse to therapy. Importantly, in the current study, fluorescent probes
targeting tumor-associated protease activity allowed in vivo detection of
microscopic tumors in mice before enlargement of the ovary detectable
by MRI. In addition, FMT coupled with a fluorescent probe detecting
integrin αvβ3 binding enabled in vivo detection of both tumor progres-
sion and response to chemotherapy. The αvβ3 integrin binding signal
detected in ovarian tumors may be from tumor cells, tumor vasculature
or both. However, the FMT2500 instrumentation is not sufficiently
sensitive to discriminate between these possibilities.
The findings in this study support additional investigation of
molecular imaging for in vivo early detection of ovarian tumors and
for detection of functional response to targeted therapy. Some targeted
and immune-based therapeutic agents show efficacy in the absence of
radiologic evidence of tumor regression or in some cases after initial
evidence of progressive disease [36,37]. Therefore, optical assessments
of biologic activities within tumors may provide relevant information
regarding response to therapy in the absence of detectable changes in
tumor volume achieved by anatomic imaging. Although beyond the
scope of the present study, demonstration of value added by FMT-
based imaging to the already highly sensitive and reliable anatomic
imaging provided by MRI will require additional studies, the success
of which will require the identification of a molecular targeted agent
with significant antitumor activity for EOC and the availability of
fluorescent probes that bind to or are activated by relevant downstream
biologic mediators of the pathway targeted.
Until recently, in vivo optical imaging strategies primarily relied
on planar imaging methods (e.g., fluorescence reflectance or bio-
luminescent imaging) that, although informative, are nonquantitative
and subject to significant limitations of light penetration and scattering
in tissues [13]. Improvements in tomographic optical imaging tech-
nology and fluorescent imaging probes with high target-to-background
ratios and low tissue autofluorescence led to the availability of FMT
instrumentation and its application for small animal imaging [38].
Whereas FMT instrumentation theoretically enables imaging of fluo-
rescent signals at depths more than 500 μm, there is little available
information regarding in vivo fluorescent molecular imaging of ovarian
tumors in mice. Previous studies in mice with xenografts of human
EOC cells demonstrated the feasibility of optical imaging using fluores-
cent probes for detection of tumor nodules but largely relied on ex vivo
FRI [39,40]. The results of this study demonstrate for the first time the
feasibility, sensitivity, and accuracy of fluorescent imaging probes and
FMT for in vivo detection of spontaneous ovarian tumors in black mice
and for quantification of tumor-associated biologic activities.
Because FMT was a new approach for in vivo imaging of spontane-
ous ovarian tumors, the combined imaging strategy increased the accu-
racy of detection and quantification of tumor-specific fluorescent probe
activation/retention. The major challenge in image alignment was due
to the gravitational effects on the organs in mice imaged in the vertical
position for MRI compared with the horizontal position for FMT.
Co-administration of AnnexinVivo to mark the kidneys for image
alignment helped overcome this challenge. The observation of high
AnnexinVivo probe accumulation in the kidneys is consistent with pre-
vious reports showing increased apoptosis and accumulation of exposed
phosphatidyl serine in the proximal tubules of kidney after isoflurane
Figure 5. Detection of ovarian tumors with IntegriSense 680 and MMPSense 680 probes. (A) MR image showing bilateral ovarian tumors
(arrows), (B) fused FMT-MR image, and (C) TrueQuant images of a mouse injected systemically with IntegriSense 680 and AnnexinVivo
750. (D) MR, (E) fused FMT-MR, and (F) TrueQuant images of a mouse injected systemically with MMPSense 680 and AnnexinVivo 750.
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inhalation [41] as well as studies using technetium 99m–conjugated
annexin V imaging agents showing that these agents are retained in
the kidneys of mice and humans [42,43]. Given the proximal location
of kidneys to the ovaries, this approach was more effective than external
installation of fiducial markers and allowed the use of the same anatomic
structure as a fiducial for serial images. The imaging methods described
in this work will be easily adaptable to imaging mice with orthotopic
implants of human ovarian cancer cells or patient tumor tissue in the
intrabursal space [17].
Technical limitations related to the depth of tissue imaging make
clinical adaptation of FMT imaging unlikely. However, the develop-
ment of combination fluorescent and white light endoscopes has al-
lowed in vivo imaging of disseminated peritoneal tumor nodules
using cathepsin activatable or small-molecule fluorescent imaging
probes [44,45]. The use of fluorescent imaging probes with high tumor-
to-background ratios results in increased sensitivity and specificity in
the detection of tumor nodules compared to white light imaging. Con-
tinued advancements in clinical adaptation of endoscopic fluorescent
imaging technology and approval of activatable and/or targeted fluores-
cent probes for clinical use are predicted to improve surgical staging and
optimal surgical debulking by detection of small disseminated lesions
that are not visible by conventional white light imaging.
The need for alternative therapies for EOC is underscored by the
common development of resistance to standard cytotoxic chemother-
apy and the persistently high mortality rate associated with advanced
stage ovarian cancer [46]. Many targeted molecular therapies are
available, several of which have been evaluated in clinical trials; how-
ever, there are few examples with demonstrated clinical efficacy for the
majority of patients. Given the high degree of tumor heterogeneity [4],
EOC treatment may require a more individualized approach. High-
throughput genomic and proteomic analyses of individual tumor spec-
imens may identify genes and signaling pathways that contribute to
cancer progression, but determining the most effective single agents or
combinations remains a significant challenge. Studies in mouse models
Figure 6. Serial FMT imaging detecting tumor progression and response to chemotherapy. Mice (n = 8) were injected with IntegriSense
680 and received baseline FMT and MRI scans 24 hours later. Immediately after the baseline scan, mice were either injected with
vehicle (n = 4) or were treated with combination chemotherapy (n = 4) and subsequently imaged twice at 12-day intervals (image 1 =
day 12, image 2 = day 24). Representative images are shown for untreated (A) and chemotherapy-treated (B) mice, with baseline images
on top and the second serial image at the bottom. A strong correlationwas observed between tumor volumebyMRI (C) and probe retention
(D). Mean values ± SEM of the treated (red lines) and untreated (blue lines) mice are shown, and the mean differences in tumor size and
probe retention in treated and untreated mice were significant (P < .001).
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have the potential to facilitate the rapid evaluation of novel agents and
effective drug combinations. Whereas the standard assessment of re-
sponse to therapy is tumor regression, disease stabilization may be
an acceptable clinical outcome. Multimodal imaging approaches for
evaluation of changes in metabolic or biologic activity of the tumor
may suggest a positive response to treatment. Further development
of fluorescent molecular imaging probes is predicted to result in addi-
tional agents that can be used as biomarkers of functional response to a
variety of targeted therapies. Importantly, the use of FMT for fluores-
cent imaging in preclinical models can provide quantitative informa-
tion regarding specific probe activation and retention as well as
response to therapy and is predicted to have translational applications
for detection, staging, and treatment of ovarian cancer.
Acknowledgments
The authors thank Margie Clapper, Michael Seiden, Timothy Yen,
and Ronald Wolf for helpful discussions and critical review of this
article.
References
[1] Jemal A, Siegel R, Xu J, and Ward E (2010). Cancer statistics, 2010. CA Cancer
J Clin 60, 277–300.
[2] Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS,
Vanderhyden BC, and Hamilton TC (2003). Female mice chimeric for expres-
sion of the simian virus 40 TAg under control of the MISIIR promoter develop
epithelial ovarian cancer. Cancer Res 63, 1389–1397.
[3] Cheng J, DeCaprio JA, Fluck MM, and Schaffhausen BS (2009). Cellular trans-
formation by Simian virus 40 andmurine polyoma virus T antigens. Semin Cancer
Biol 19, 218–228.
[4] Network TCGAR (2011). Integrated genomic analyses of ovarian carcinoma.
Nature 474, 609–615.
[5] Kurman RJ and Shih Ie M (2010). The origin and pathogenesis of epithelial
ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34, 433–443.
[6] Hensley H, Quinn BA, Wolf RL, Litwin SL, Mabuchi S, Williams SJ, Williams
C, Hamilton TC, and Connolly DC (2007). Magnetic resonance imaging for
detection and determination of tumor volume in a genetically engineered mouse
model of ovarian cancer. Cancer Biol Ther 6, 1717–1725.
[7] Quinn BA, Xiao F, Bickel L, Martin L, Hua X, Klein-Szanto A, and Connolly
DC (2010). Development of a syngeneic mouse model of epithelial ovarian can-
cer. J Ovarian Res 3, 24.
[8] Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle
MK, Hensley HH, Hamilton TC, and Testa JR (2007). RAD001 (everolimus)
delays tumor onset and progression in a transgenic mouse model of ovarian can-
cer. Cancer Res 67, 2408–2413.
[9] Weissleder R (2006). Molecular imaging in cancer. Science 312, 1168–1171.
[10] Grimm J, Kirsch DG, Windsor SD, Kim CF, Santiago PM, Ntziachristos V,
Jacks T, and Weissleder R (2005). Use of gene expression profiling to direct in vivo
molecular imaging of lung cancer. Proc Natl Acad Sci USA 102, 14404–14409.
[11] Kirsch DG, Dinulescu DM, Miller JB, Grimm J, Santiago PM, Young NP,
Nielsen GP, Quade BJ, Chaber CJ, Schultz CP, et al. (2007). A spatially and tem-
porally restricted mouse model of soft tissue sarcoma. Nat Med 13, 992–997.
[12] Weissleder R and Ntziachristos V (2003). Shedding light onto live molecular
targets. Nat Med 9, 123–128.
[13] Ntziachristos V, Ripoll J, Wang LV, and Weissleder R (2005). Looking and
listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol
23, 313–320.
[14] Zacharakis G, Kambara H, Shih H, Ripoll J, Grimm J, Saeki Y, Weissleder R,
and Ntziachristos V (2005). Volumetric tomography of fluorescent proteins
through small animals in vivo. Proc Natl Acad Sci USA 102, 18252–18257.
[15] Kossodo S, Pickarski M, Lin SA, Gleason A, Gaspar R, Buono C, Ho G,
Blusztajn A, Cuneo G, Zhang J, et al. (2009). Dual in vivo quantification of
integrin-targeted and protease-activated agents in cancer using fluorescence mo-
lecular tomography (FMT). Mol Imaging Biol 12, 488–499.
[16] Graves EE, Weissleder R, and Ntziachristos V (2004). Fluorescence molecular
imaging of small animal tumor models. Curr Mol Med 4, 419–430.
[17] Connolly DC and Hensley HH (2009). Xenograft and transgenic mouse mod-
els of epithelial ovarian cancer and non-invasive imaging modalities to monitor
ovarian tumor growth in situ: applications in evaluating novel therapeutic
agents. Current Protoc Pharmacol 45, 14.12.11–14.12.36.
[18] Rorden C and Brett M (2000). Stereotaxic display of brain lesions. Behav Neurol
12, 191–200.
[19] Loening AM and Gambhir SS (2003). AMIDE: a free software tool for multi-
modality medical image analysis. Mol Imaging 2, 131–137.
[20] Chai Y, Wu W, Zhou C, and Zhou J (2012). The potential prognostic value of
cathepsin D protein in serous ovarian cancer. Arch Gynecol Obstet. E-pub ahead
of print.
[21] Downs LS Jr, Lima PH, Bliss RL, and Blomquist CH (2005). Cathepsins B and
D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and
epithelial ovarian cancer. J Soc Gynecol Investig 12, 539–544.
[22] Losch A, Schindl M, Kohlberger P, Lahodny J, Breitenecker G, Horvat R, and
Birner P (2004). Cathepsin D in ovarian cancer: prognostic value and correla-
tion with p53 expression and microvessel density. Gynecol Oncol 92, 545–552.
[23] Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RC Jr, and Stack MS
(1994). Secretion of extracellular matrix–degrading proteinases is increased in
epithelial ovarian carcinoma. Int J Cancer 56, 552–559.
[24] Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E, Fridman R,
Berger U, Schmitt M, Kuhn W, et al. (2001). Increased expression of matrix
metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen ac-
tivator is associated with progression from benign to advanced ovarian cancer.
Clin Cancer Res 7, 2396–2404.
[25] Beck V, Herold H, Benge A, Luber B, Hutzler P, Tschesche H, Kessler H,
Schmitt M, Geppert HG, and Reuning U (2005). ADAM15 decreases integrin
αvβ3/vitronectin–mediated ovarian cancer cell adhesion and motility in an
RGD-dependent fashion. Int J Biochem Cell Biol 37, 590–603.
[26] Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth
WA, Nick AM, Jennnings NB, Kinch MS, et al. (2008). Tumor-selective re-
sponse to antibody-mediated targeting of αvβ3 integrin in ovarian cancer. Neo-
plasia 10, 1259–1267.
[27] Leroy-Dudal J, Demeilliers C, Gallet O, Pauthe E, Dutoit S, Agniel R,
Gauduchon P, and Carreiras F (2005). Transmigration of human ovarian ade-
nocarcinoma cells through endothelial extracellular matrix involves αv integrins
and the participation of MMP2. Int J Cancer 114, 531–543.
[28] Bremer C, Ntziachristos V, Weitkamp B, Theilmeier G, Heindel W, and
Weissleder R (2005). Optical imaging of spontaneous breast tumors using pro-
tease sensing “smart” optical probes. Invest Radiol 40, 321–327.
[29] von Wallbrunn A, Holtke C, Zuhlsdorf M, Heindel W, Schafers M, and
Bremer C (2007). In vivo imaging of integrin αvβ3 expression using fluores-
cence-mediated tomography. Eur J Nucl Med Mol Imaging 34, 745–754.
[30] Athanassiadou P, Sakellariou V, Petrakakou E, Athanassiades P, Zerva C, Liossi
A, and Michalas S (1998). Cathepsin D immunoreactivity in ovarian cancer:
correlation with prognostic factors. Pathol Oncol Res 4, 103–107.
[31] Baekelandt M, Holm R, Trope CG, Nesland JM, and Kristensen GB (1999).
The significance of metastasis-related factors cathepsin-D and nm23 in ad-
vanced ovarian cancer. Ann Oncol 10, 1335–1341.
[32] Fishman DA, Liu Y, Ellerbroek SM, and Stack MS (2001). Lysophosphatidic
acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent
invasion in ovarian cancer cells. Cancer Res 61, 3194–3199.
[33] Naylor MS, Stamp GW, Davies BD, and Balkwill FR (1994). Expression
and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 58,
50–56.
[34] Sakata K, Shigemasa K, Nagai N, and Ohama K (2000). Expression of matrix
metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors
(TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol
17, 673–681.
[35] Scambia G, Panici PB, Ferrandina G, Salerno G, D’Agostino G, Distefano M,
de Vincenzo R, Ercoli A, andMancuso S (1994). Clinical significance of cathepsin
D in primary ovarian cancer. Eur J Cancer 30A, 935–940.
[36] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R,
Dancey J, Arbuck S, Gwyther S, Mooney M, et al. (2009). New response eval-
uation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur
J Cancer 45, 228–247.
[37] Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, Maio M,
Binder M, Bohnsack O, Nichol G, et al. (2009). Guidelines for the evaluation
of immune therapy activity in solid tumors: immune-related response criteria.
Clin Cancer Res 15, 7412–7420.
Neoplasia Vol. 14, No. 6, 2012 Molecular Imaging of EOC in Transgenic Mice Hensley et al. 461
[38] Hilderbrand SA and Weissleder R (2009). Near-infrared fluorescence: applica-
tion to in vivo molecular imaging. Curr Opin Chem Biol 14, 71–79.
[39] Gunn AJ, Hama Y, Koyama Y, Kohn EC, Choyke PL, and Kobayashi H
(2007). Targeted optical fluorescence imaging of human ovarian adenocarcinoma
using a galactosyl serum albumin-conjugated fluorophore. Cancer Sci 98,
1727–1733.
[40] Hama Y, Urano Y, Koyama Y, Gunn AJ, Choyke PL, and Kobayashi H (2007).
A self-quenched galactosamine-serum albumin-rhodamineX conjugate: a
“smart” fluorescent molecular imaging probe synthesized with clinically appli-
cable material for detecting peritoneal ovarian cancer metastases. Clin Cancer Res
13, 6335–6343.
[41] Lee HT, Kim M, Kim J, Kim N, and Emala CW (2007). TGF-β1 release by
volatile anesthetics mediates protection against renal proximal tubule cell necrosis.
Am J Nephrol 27, 416–424.
[42] Kemerink GJ, Liu X, Kieffer D, Ceyssens S, Mortelmans L, Verbruggen AM,
Steinmetz ND, Vanderheyden JL, Green AM, and Verbeke K (2003).
Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel
human recombinant annexin V for human application. J Nucl Med 44,
947–952.
[43] Tait JF, Smith C, and Blankenberg FG (2005). Structural requirements for
in vivo detection of cell death with 99mTc-annexin V. J Nucl Med 46,
807–815.
[44] Kosaka N, Mitsunaga M, Longmire MR, Choyke PL, and Kobayashi H (2011).
Near infrared fluorescence-guided real-time endoscopic detection of peritoneal
ovarian cancer nodules using intravenously injected indocyanine green. Int
J Cancer 129, 1671–1677.
[45] Sheth RA, Upadhyay R, Stangenberg L, Sheth R, Weissleder R, and Mahmood U
(2009). Improved detection of ovarian cancer metastases by intraoperative
quantitative fluorescence protease imaging in a pre-clinical model. Gynecol Oncol
112, 616–622.
[46] Bast RC Jr, Hennessy B, and Mills GB (2009). The biology of ovarian cancer:
new opportunities for translation. Nat Rev Cancer 9, 415–428.
462 Molecular Imaging of EOC in Transgenic Mice Hensley et al. Neoplasia Vol. 14, No. 6, 2012
Figure W1. FMT2500 and fused FMT-MR images. (A) A wild-type
C57BL/6 mouse was injected with ProSense 680 and AnnexinVivo
750 at 24 and 2 hours before imaging, respectively. Upper panels
show the three-dimensional fluorescent images acquired using
the (a) 680-nm, (b) 750-nm, and (c) merged 680- and 750-nm chan-
nels of the FMT2500 imaging system. Each of the images in a to c
were converted usingAMIDEand are shown for the 750- and 680-nm
channels (d and e) and merged 680- and 750-nm channels (f).
(B) Fluorescent images acquired using the (a) 680-nm, (b) 750-nm,
and (c) merged 680- and 750-nm channels of the FMT2500 imaging
system from a tumor-bearing TgMISIIR-TAg mouse injected with
ProSense 680 and AnnexinVivo 750 at 24 and 2 hours before imag-
ing, respectively. The regions corresponding to bilateral tumors are
outlined in white (680-nm image, subpanel a).
Figure W2. Alignment ofMRandFMT imagesusingAnnexinVivo 750. TheMRand fluorescent FMT images fromwild-type (WT)C57BL/6 and
tumor-bearing TgMISIIR-TAg (TAg+)mice injectedwith ProSense 680 and AnnexinVivo 750 (A-F) or ProSense Control probe and AnnexinVivo
750 (G-I) were aligned using AMIDE. (A, D, and G) MR images showing the ovaries and ovarian tumors (arrows) and kidneys (k). (B, E, and H)
Fused images showingmerged fluorescent signals detected in the 680- (ProSense or ProSense Control) and 750-nm (AnnexinVivo) channels.
(C, F, and I) MR image aligned with both the fluorescent images, showing no probe activation in the normal (wild-type) ovaries (C) or in the
ovarian tumors in control probe injected mice (I). Activated probe signal aligns with the ovarian tumors in the ProSense-injected mouse (F).
Movie W1. Three-dimensional rendering of images acquired by
FMT and MRI. A TgMISIIR-TAg transgenic mouse with bilateral
ovarian tumors was injected with ProSense 680 and AnnexinVivo
750 and subjected to FMT and MRI scanning of the entire abdo-
men. The three-dimensional FMT and MRI data sets were then
aligned using AMIDE and rendered to show the anatomic and fluo-
rescent data in three dimensions.
